Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 6/20 | 0.55 |
| ▸ | AKT2 | P31751 | 7/20 | 0.53 |
| ▸ | KIT | P10721 | 5/20 | 0.52 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.51 |
| ▸ | PRKACA | P17612 | 2/20 | 0.51 |
| ▸ | PRKACG | P22612 | 2/20 | 0.51 |
| ▸ | PRKACB | P22694 | 2/20 | 0.51 |
| ▸ | LIMK1 | P53667 | 2/20 | 0.51 |
| ▸ | LIMK2 | P53671 | 2/20 | 0.51 |
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
| ▸ | CSF1R | P07333 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3493479 | 0.87 | AKT2 (0.63) | AKT1AKT2KITROCK2GSK3B | |
| SCHEMBL13510877 | 0.83 | AKT1 (0.73) | AKT1AKT2KITROCK2GSK3B | |
| SCHEMBL3491999 | 0.83 | AKT2 (0.60) | AKT1AKT2KITROCK2PRKACA | |
| SCHEMBL3492324 | 0.82 | AKT2 (0.58) | AKT1AKT2ROCK2PRKACAPRKACG | |
| SCHEMBL3491790 | 0.80 | AKT2 (0.56) | AKT1AKT2KITROCK2PRKACA | |
| SCHEMBL13343923 | 0.79 | AKT1 (0.68) | AKT1AKT2ROCK2GSK3BKCNH2 | |
| SCHEMBL3491738 | 0.78 | AKT1 (0.68) | AKT1AKT2ROCK2GSK3BKCNH2 | |
| SCHEMBL3494310 | 0.78 | AKT1 (0.60) | AKT1AKT2KITROCK2PRKACA | |
| SCHEMBL3490712 | 0.78 | TRPV1 (0.44) | CSF1R | |
| SCHEMBL13343977 | 0.78 | AKT2 (0.79) | AKT1AKT2ROCK2CSF1RKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100120798-A1 | SUBSTITUTED PIPERIDINES CONTAINING A HETEROARYLAMIDE OR HETEROARYLPHENYL MOIETY | ASTEX THERAPEUTICS LIMITED (GB) | 2010-05-13 | — | — | US | claimed |
| US-20100120798-A1 | SUBSTITUTED PIPERIDINES CONTAINING A HETEROARYLAMIDE OR HETEROARYLPHENYL MOIETY | ASTEX THERAPEUTICS LIMITED (GB) | 2010-05-13 | — | — | US | disclosed |
| US-20100120798-A1 | SUBSTITUTED PIPERIDINES CONTAINING A HETEROARYLAMIDE OR HETEROARYLPHENYL MOIETY | ASTEX THERAPEUTICS LIMITED (GB) | 2010-05-13 | — | — | US | disclosed |
| US-20100120798-A1 | SUBSTITUTED PIPERIDINES CONTAINING A HETEROARYLAMIDE OR HETEROARYLPHENYL MOIETY | ASTEX THERAPEUTICS LIMITED (GB) | 2010-05-13 | — | — | US | disclosed |
| WO-2008075110-A1 | SUBSTITUTED PIPERIDINES CONTAINING A HETEROARYLAMIDE OR HETEROARYLPHENYL MOIETY | ASTEX THERAPEUTICS LIMITED (GB) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120798-A1 | SUBSTITUTED PIPERIDINES CONTAINING A HETEROARYLAMIDE OR HETEROARYLPHENYL MOIETY | GRK2, GNAO1, PTGER1 | AKT1 40/4885AKT2 27/4885KIT 1421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.